Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, has scheduled the release of its fourth quarter and full-year 2024 financial results for March 11, 2025, before market opening. The company will host a conference call at 8:30 AM ET (5:30 AM PT) with President and CEO John Aballi and CFO Jeff Black to discuss the results.
Participants can join via phone at 201-389-0918 (U.S.) or +1-877-407-0890 (international), or through webcast available on the company's investor relations website. A replay will be accessible until April 14, 2025, at 11:59 PM ET through phone (201-612-7415 U.S., +1-877-660-6853 international, passcode 13751928) or webcast.
Exagen Inc. (Nasdaq: XGN), un fornitore leader di test autoimmuni, ha programmato il rilascio dei suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 per l'11 marzo 2025, prima dell'apertura del mercato. L'azienda ospiterà una conference call alle 8:30 AM ET (5:30 AM PT) con il Presidente e CEO John Aballi e il CFO Jeff Black per discutere i risultati.
I partecipanti possono unirsi via telefono al numero 201-389-0918 (U.S.) o +1-877-407-0890 (internazionale), oppure tramite webcast disponibile sul sito web delle relazioni con gli investitori dell'azienda. Una registrazione sarà accessibile fino al 14 aprile 2025, alle 11:59 PM ET, tramite telefono (201-612-7415 U.S., +1-877-660-6853 internazionale, codice di accesso 13751928) o webcast.
Exagen Inc. (Nasdaq: XGN), un proveedor líder de pruebas autoinmunitarias, ha programado la publicación de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 11 de marzo de 2025, antes de la apertura del mercado. La compañía llevará a cabo una llamada de conferencia a las 8:30 AM ET (5:30 AM PT) con el Presidente y CEO John Aballi y el CFO Jeff Black para discutir los resultados.
Los participantes pueden unirse por teléfono al 201-389-0918 (EE. UU.) o +1-877-407-0890 (internacional), o a través de un webcast disponible en el sitio web de relaciones con inversores de la compañía. Una repetición estará accesible hasta el 14 de abril de 2025, a las 11:59 PM ET, a través del teléfono (201-612-7415 EE. UU., +1-877-660-6853 internacional, código de acceso 13751928) o webcast.
Exagen Inc. (Nasdaq: XGN), 자가면역 검사 분야의 선도적인 공급업체는 2024년 4분기 및 연간 재무 결과를 2025년 3월 11일, 시장 개장 전 발표할 예정입니다. 회사는 결과를 논의하기 위해 오전 8시 30분 ET(오전 5시 30분 PT)에 회장 겸 CEO인 John Aballi와 CFO인 Jeff Black과 함께 컨퍼런스 콜을 진행할 것입니다.
참가자는 전화로 201-389-0918(미국) 또는 +1-877-407-0890(국제)로 참여하거나 회사의 투자자 관계 웹사이트에서 제공되는 웹캐스트를 통해 참여할 수 있습니다. 녹화는 2025년 4월 14일 오후 11시 59분 ET까지 전화(201-612-7415 미국, +1-877-660-6853 국제, 패스코드 13751928) 또는 웹캐스트를 통해 접근할 수 있습니다.
Exagen Inc. (Nasdaq: XGN), un fournisseur leader de tests auto-immuns, a programmé la publication de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 11 mars 2025, avant l'ouverture du marché. L'entreprise tiendra une conférence téléphonique à 8h30 ET (5h30 PT) avec le Président et CEO John Aballi et le CFO Jeff Black pour discuter des résultats.
Les participants peuvent se joindre par téléphone au 201-389-0918 (États-Unis) ou +1-877-407-0890 (international), ou via un webcast disponible sur le site web des relations investisseurs de l'entreprise. Un enregistrement sera accessible jusqu'au 14 avril 2025, à 23h59 ET, par téléphone (201-612-7415 États-Unis, +1-877-660-6853 international, code d'accès 13751928) ou par webcast.
Exagen Inc. (Nasdaq: XGN), ein führender Anbieter von Autoimmun-Tests, hat die Veröffentlichung seiner Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 für den 11. März 2025, vor Markteröffnung, angesetzt. Das Unternehmen wird um 8:30 Uhr ET (5:30 Uhr PT) eine Telefonkonferenz mit Präsident und CEO John Aballi sowie CFO Jeff Black abhalten, um die Ergebnisse zu besprechen.
Teilnehmer können telefonisch unter 201-389-0918 (USA) oder +1-877-407-0890 (international) teilnehmen oder über den Webcast, der auf der Investor-Relations-Website des Unternehmens verfügbar ist. Eine Wiederholung wird bis zum 14. April 2025 um 23:59 Uhr ET über das Telefon (201-612-7415 USA, +1-877-660-6853 international, Zugangscode 13751928) oder Webcast zugänglich sein.
- None.
- None.
CARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2024, before the market opens on Tuesday, March 11, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 AM ET (5:30 AM PT).
Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.
A replay of the conference call will be available until Monday, April 14, 2025, at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay by dialing 201-612-7415 (U.S.) or +1-877-660-6853 (international) using passcode 13751928. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.
About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
For more information, visit Exagen.com or follow @ExagenInc on X.
Contact:
Ryan Douglas
Exagen Inc.
ir@exagen.com
760.560.1525
FAQ
When will Exagen (XGN) release its Q4 and full-year 2024 earnings?
How can investors join Exagen's (XGN) Q4 2024 earnings call?
What time is Exagen's (XGN) Q4 2024 earnings conference call?
Until when will Exagen's (XGN) Q4 2024 earnings call replay be available?
